Compare CLAR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | KLRS |
|---|---|---|
| Founded | 1957 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.9M | 92.8M |
| IPO Year | 1998 | 2020 |
| Metric | CLAR | KLRS |
|---|---|---|
| Price | $3.36 | $2.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $3.50 | ★ $18.71 |
| AVG Volume (30 Days) | ★ 91.7K | 50.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | 11.68 | ★ 75.70 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $228,000.00 | $165,000.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | $85.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.53 | $2.81 |
| 52 Week High | $3.98 | $11.88 |
| Indicator | CLAR | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 26.31 |
| Support Level | $3.29 | N/A |
| Resistance Level | $3.50 | $4.37 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.00 | 18.71 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.